Use the search bar to search by drug, manufacturer, or indication. You can also filter your search results by drug, manufacturer, or negotiation status.
To learn more about a specific file, click on a drug name. It will open its product card, which includes information about the manufacturer, indication (the approved use of a drug by Health Canada), and negotiation milestones.
There are 6 negotiation statuses, which reflect where the drug file is in the pCPA process:
Under consideration for negotiation
We’re considering the evidence and gathering other information to inform the negotiation approach, including eligibility for expedited negotiation pathways.
Active negotiation
Negotiation activities are underway for the drug, with our negotiation team and the manufacturer meeting regularly.
Concluded with an LOI
Negotiations ended successfully with mutually agreed-upon terms, and these terms are outlined in a letter of intent (LOI).
Concluded without agreement
Negotiating parties couldn’t agree on terms. Negotiations have ended without a pricing agreement for the drug.
Negotiation not pursued
It has been decided, in partnership with our member drug plans, not to engage in a negotiation. Typically, this is because the drug’s health technology (HTA) assessment reimbursement recommendations were negative, or “do not reimburse.” Other reasons, like the manufacturer declining to negotiate or a lack of supply of the drug in Canada, may be reflected in an accompanying status note.
Negotiation on hold
We began negotiation activities for the drug, but they’ve since been paused. An accompanying status note indicates whether the pause was requested by the manufacturer or the pCPA.
Downloads
Exports from our negotiations database are available for download in CSV or JSON formats.
Learn more
To learn more about our negotiation processes, or where the pCPA fits into the Canadian drug reimbursement system, consult these pages:
Status:
Concluded with an LOI
Manufacturer:
Amgen Canada Inc.
Indication:
Indicated for the pediatric patients with Philadelphia chromosome negative relapsed/refractory B precursor acute lymphoblastic leukemia (ALL) who are in first relapse.
Last updated:
September 29, 2025
Status:
Concluded with an LOI
Manufacturer:
Ethypharm Inc.
Indication:
for the treatment of essential or renovascular hypertension; for the treatment of congestive heart failure; to improve survival, delay the onset of symptomatic heart failure and reduce hospitalizations for heart failure following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction of ? 40%; for the treatment of diabetic nephropathy (proteinuria ? 500 mg/day) in patients with type I insulin-dependent diabetes mellitus and retinopathy.
Last updated:
September 22, 2025
Status:
Concluded with an LOI
Manufacturer:
GlaxoSmithKline Inc.
Indication:
For the treatment of splenomegaly and/or disease-related symptoms, in adult patients with intermediate or high-risk primary myelofibrosis (MF), post polycythemia vera myelofibrosis or post essential thrombocythemia MF who have moderate to severe anemia.
Last updated:
September 22, 2025
Hemgenix (etranacogene dezaparvovec)
Status:
Concluded with an LOI
Manufacturer:
CSL Behring Canada Inc.
Indication:
Hemophilia B
Last updated:
September 22, 2025
Carvykti (ciltacabtagene autoleucel)
Status:
Concluded without agreement
Manufacturer:
Janssen Inc.
Indication:
For the treatment of adult patients with multiple myeloma, who have received 1 to 3 prior lines of therapy including a proteasome inhibitor and an immunomodulatory agent, and who are refractory to lenalidomide.
Last updated:
September 18, 2025